Welch & Forbes LLC Bristol Myers Squibb CO Transaction History

Welch & Forbes LLC

$7.73 Billion
Q3 2024

A detailed history of Welch & Forbes LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Welch & Forbes LLC holds 107,719 shares of BMY stock, worth $6.25 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

107,719

Previous 112,109 3.92%

Holding current value

$6.25 Million

Previous $4.66 Million 19.74%

% of portfolio

0.07%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$39.66 - $51.75 $174,107 - $227,182	-4,390 Reduced 3.92%	107,719 $5.57 Million
Q2 2024 Aug 01, 2024	SELL	$40.25 - $52.99 $474,909 - $625,229	-11,799 Reduced 9.52%	112,109 $4.66 Million
Q1 2024 May 02, 2024	SELL	$47.98 - $54.4 $565,972 - $641,702	-11,796 Reduced 8.69%	123,908 $6.72 Million
Q4 2023 Feb 06, 2024	SELL	$48.48 - $57.85 $723,709 - $863,584	-14,928 Reduced 9.91%	135,704 $6.96 Million
Q3 2023 Nov 02, 2023	SELL	$57.89 - $64.73 $553,544 - $618,948	-9,562 Reduced 5.97%	150,632 $8.74 Million
Q2 2023 Jul 28, 2023	SELL	$63.71 - $70.74 $178,196 - $197,859	-2,797 Reduced 1.72%	160,194 $10.2 Million
Q1 2023 Apr 14, 2023	SELL	$65.71 - $74.53 $329,535 - $373,767	-5,015 Reduced 2.99%	162,991 $11.3 Million
Q4 2022 Feb 02, 2023	BUY	$68.48 - $81.09 $214,136 - $253,568	3,127 Added 1.9%	168,006 $12.1 Million
Q3 2022 Oct 28, 2022	SELL	$0.13 - $76.84 $26 - $15,829	-206 Reduced 0.12%	164,879 $11.7 Million
Q2 2022 Jul 22, 2022	SELL	$72.62 - $79.98 $665,489 - $732,936	-9,164 Reduced 5.26%	165,085 $12.7 Million
Q1 2022 Apr 25, 2022	BUY	$61.48 - $73.72 $393,779 - $472,176	6,405 Added 3.82%	174,249 $12.7 Million
Q4 2021 Jan 19, 2022	SELL	$53.63 - $62.52 $932,303 - $1.09 Million	-17,384 Reduced 9.39%	167,844 $10.5 Million
Q3 2021 Oct 13, 2021	SELL	$59.17 - $69.31 $574,067 - $672,445	-9,702 Reduced 4.98%	185,228 $11 Million
Q2 2021 Jul 22, 2021	SELL	$61.91 - $67.42 $247,268 - $269,275	-3,994 Reduced 2.01%	194,930 $13 Million
Q1 2021 Apr 14, 2021	SELL	$59.34 - $66.74 $552,455 - $621,349	-9,310 Reduced 4.47%	198,924 $12.6 Million
Q4 2020 Jan 20, 2021	SELL	$57.74 - $65.43 $342,109 - $387,672	-5,925 Reduced 2.77%	208,234 $12.9 Million
Q3 2020 Oct 23, 2020	BUY	$57.43 - $63.64 $106,590 - $118,115	1,856 Added 0.87%	214,159 $12.9 Million
Q2 2020 Jul 15, 2020	SELL	$54.82 - $64.09 $110,517 - $129,205	-2,016 Reduced 0.94%	212,303 $12.5 Million
Q1 2020 Apr 17, 2020	SELL	$46.4 - $67.43 $201,608 - $292,983	-4,345 Reduced 1.99%	214,319 $11.9 Million
Q4 2019 Jan 17, 2020	BUY	$49.21 - $64.19 $325,278 - $424,295	6,610 Added 3.12%	218,664 $14 Million
Q3 2019 Oct 11, 2019	BUY	$42.77 - $50.71 $387,068 - $458,925	9,050 Added 4.46%	212,054 $10.8 Million
Q2 2019 Jul 12, 2019	BUY	$44.62 - $49.34 $1.18 Million - $1.3 Million	26,336 Added 14.91%	203,004 $9.21 Million
Q1 2019 Apr 29, 2019	SELL	$45.12 - $53.8 $1.74 Million - $2.08 Million	-38,632 Reduced 17.94%	176,668 $8.43 Million
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $305,383 - $396,009	-6,263 Reduced 2.83%	215,300 $11.2 Million
Q3 2018 Oct 17, 2018	SELL	$55.19 - $62.25 $191,067 - $215,509	-3,462 Reduced 1.54%	221,563 $13.8 Million
Q2 2018 Jul 16, 2018	SELL	$50.53 - $62.98 $240,169 - $299,343	-4,753 Reduced 2.07%	225,025 $12.5 Million
Q1 2018 Apr 12, 2018	SELL	$59.92 - $68.98 $15,219 - $17,520	-254 Reduced 0.11%	229,778 $14.5 Million
Q4 2017 Jan 26, 2018	SELL	$59.94 - $65.35 $243,895 - $265,909	-4,069 Reduced 1.74%	230,032 $14.1 Million
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $12.9 Million - $14.9 Million	234,101	234,101 $14.9 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Welch & Forbes LLC, based on Form 13F filings with the SEC.

News

Stay updated on Welch & Forbes LLC with notifications on news.

Account